



# HLA Class I Supertypes: A Revised and Updated Classification

## Citation

Sidney, John, Bjoern Peters, Nicole Frahm, Christian Brander, and Alessandro Sette. 2008. HLA class I supertypes: a revised and updated classification. BMC Immunology 9: 1.

## Published Version

doi://10.1186/1471-2172-9-1

## Permanent link

<http://nrs.harvard.edu/urn-3:HUL.InstRepos:5333510>

## Terms of Use

This article was downloaded from Harvard University's DASH repository, and is made available under the terms and conditions applicable to Other Posted Material, as set forth at <http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAA>

## Share Your Story

The Harvard community has made this article openly available.  
Please share how this access benefits you. [Submit a story](#).

[Accessibility](#)

Research article

Open Access

## HLA class I supertypes: a revised and updated classification

John Sidney<sup>1</sup>, Bjoern Peters<sup>1</sup>, Nicole Frahm<sup>2</sup>, Christian Brander<sup>2</sup> and Alessandro Sette<sup>\*1</sup>

Address: <sup>1</sup>Division of Vaccine Discovery, The La Jolla Institute for Allergy and Immunology, 9420 Athena Circle, La Jolla, CA 92037, USA and <sup>2</sup>Partners AIDS Research Center, Massachusetts General Hospital, Harvard Medical School, 149 13 Street, Charlestown, MA 02129, USA

Email: John Sidney - jsidney@liai.org; Bjoern Peters - bpeters@liai.org; Nicole Frahm - nfracm@partners.org; Christian Brander - brander@helix.mgh.harvard.edu; Alessandro Sette<sup>\*</sup> - alex@liai.org

<sup>\*</sup> Corresponding author

Published: 22 January 2008

Received: 13 July 2007

BMC Immunology 2008, 9:1 doi:10.1186/1471-2172-9-1

Accepted: 22 January 2008

This article is available from: <http://www.biomedcentral.com/1471-2172/9/1>

© 2008 Sidney et al; licensee BioMed Central Ltd.

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<http://creativecommons.org/licenses/by/2.0>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

### Abstract

**Background:** Class I major histocompatibility complex (MHC) molecules bind, and present to T cells, short peptides derived from intracellular processing of proteins. The peptide repertoire of a specific molecule is to a large extent determined by the molecular structure accommodating so-called main anchor positions of the presented peptide. These receptors are extremely polymorphic, and much of the polymorphism influences the peptide-binding repertoire. However, despite this polymorphism, class I molecules can be clustered into sets of molecules that bind largely overlapping peptide repertoires. Almost a decade ago we introduced this concept of clustering human leukocyte antigen (HLA) alleles and defined nine different groups, denominated as supertypes, on the basis of their main anchor specificity. The utility of this original supertype classification, as well several other subsequent arrangements derived by others, has been demonstrated in a large number of epitope identification studies.

**Results:** Following our original approach, in the present report we provide an updated classification of HLA-A and -B class I alleles into supertypes. The present analysis incorporates the large amount of class I MHC binding data and sequence information that has become available in the last decade. As a result, over 80% of the 945 different HLA-A and -B alleles examined to date can be assigned to one of the original nine supertypes. A few alleles are expected to be associated with repertoires that overlap multiple supertypes. Interestingly, the current analysis did not identify any additional supertype specificities.

**Conclusion:** As a result of this updated analysis, HLA supertype associations have been defined for over 750 different HLA-A and -B alleles. This information is expected to facilitate epitope identification and vaccine design studies, as well as investigations into disease association and correlates of immunity. In addition, the approach utilized has been made more transparent, allowing others to utilize the classification approach going forward.

### Background

Class I major histocompatibility complex (MHC) molecules bind short peptides derived from the processing of

proteins, and present them on the cell surface for T cell scrutiny. Functional MHC molecules are made of a heavy ( $\alpha$ ) chain and a  $\beta$ 2-microglobulin chain. Peptide binding

by class I molecules is accomplished by interaction of the peptide amino acid side chains with discrete pockets within the peptide-binding groove of the MHC molecule formed by the  $\alpha 1$  and  $\alpha 2$  domains of the heavy chain. Typically, in the case of human leukocyte antigen (HLA) class I, the main binding energy is provided by the interaction of residues in position 2 and the C-terminus of the peptide with the B and F binding pockets of the MHC molecule, respectively [1-8], although side chains throughout the ligand can have a positive or negative influence on binding capacity. The common chemical specificity of the peptide side chains amongst ligands bound by a specific MHC molecule is termed the binding motif [9].

MHC molecules are extremely polymorphic, and over a thousand allelic variants have already been described at the class I A and B loci. Most of the polymorphism is located in the peptide-binding region, and as a result each variant is believed to bind a unique repertoire of peptide ligands. Despite this polymorphism, HLA class I molecules can be clustered into groups, designated as supertypes, representing sets of molecules that share largely overlapping peptide binding specificity. Each supertype can be described by a supermotif that reflects the broad main anchor motif recognized by molecules within the corresponding supertype. For example, molecules of the A2-supertype share specificity for peptides with aliphatic hydrophobic residues in position 2 and at the C-terminus, while A3-supertype molecules recognize peptides with small or aliphatic residues in position 2 and basic residues at the C-terminus.

The first supertypes were described in the mid-1990's by our group [10]. Using motifs derived from binding data or the sequencing of endogenously bound ligands, along with simple structural analyses, nine different supertypes were defined [11,12]. Initial peptide binding studies allowed the identification of several peptides with degenerate binding capacity for the A2- [13-15], A3- [16-18] and B7-supertypes [19,20]. In subsequent years, additional binding data have been published to confirm the B44- [21], A1- and A24-supertypes [22].

Over time, a number of different and more sophisticated computational approaches have been implemented by others to classify HLA class I alleles into clusters or supertypes [23-32]. While in general agreement, additional supertypes, representing either sub-clusters of the original nine or completely novel groupings, have been proposed [23,32]. Despite differences in various classification schemes, the concept of HLA supertypes has been effectively used to characterize and identify promiscuously recognized T cell epitopes from a variety of different disease targets, including measles-mumps-rubella [33], SARS

[34], EBV [35,36], HIV [37-41], Kaposi' Sarcoma Associated Human Herpesvirus [42,43], HCV [16,44], HBV [45,46], HPV [47], influenza [48], *P. falciparum* [49-52], LCMV [53], Lassa virus [54], *F. tularensis* [55], vaccinia [56-58], and also cancer antigens [59-68]. Supertypes have also been utilized as a component in several approaches and algorithms designed for predicting peptide candidates with degenerate HLA class I binding capacity [69-77]. Finally, supertypes have also been examined as a variable in studies of disease association, rates of susceptibility, and outcome [37,78-86].

The original classification proposed by Sette and Sidney [12] comprised about 100 different class I MHC alleles. However, over the last 10 years, substantially more binding data has been generated, and through the efforts of several seminal MHC-related databases, including SYF-PEITHI [87], HLA Ligand [88], FIMM [89] and MHCBN [90], MHC binding motif information is readily accessible. Up-to-date compilations of MHC sequence data are also readily available in the IMGT database [91]. Herein, we analyze the complete list of alleles available through IMGT (release 2.9) using a simple approach largely based on compilation of published motifs, binding data, and analyses of shared repertoires of binding peptides, in conjunction with clustering based on the primary sequence of the B and F peptide binding pockets. As a result, we now provide updated supertype assignments, with new assignments for about 700 different HLA-A and -B alleles. This will permit the use of our original classification scheme based on current data and its comparison to alternative supertype classification methodologies developed since then.

## Results

### **MHC sequences and peptide binding pockets**

$\alpha 1$  and 2 chain residues comprising the B and F peptide-binding pockets of 945 HLA A and B class I molecules were extracted and aligned. Based on crystallographic studies [1,4,6,8], residues 7, 9, 24, 34, 45, 63, 66, 67, 70, and 99 were considered as comprising the B pocket, which engages the peptide residue in position 2. The residues comprising the F pocket, which engages the peptide C-terminal residue, were defined as 74, 77, 80, 81, 84, 95, 97, 114, 116, 123, 133, 143, 146, and 147. Further, for the B pocket we defined the subset of residues 9, 45, 63, 66, 67, 70, and 99 as key residues. In the F pocket, the key residues are those in positions 77, 80, 81 and 116.

### **Pocket chemical specificity**

Next, we defined the broad chemical specificity associated with the different B and F pockets. Table 1 summarizes the amino acid residues generally associated with each particular description of binding specificity. The particular set of residues associated with each use of a descriptor may vary

**Table 1: Physiochemical functionality of peptide side chains.**

Pocket specificity	Associated amino acid residues
Acidic	DE
Aliphatic	LIVMQ
Aromatic	FWY
Aromatic and aliphatic	FWYLIVMQ
Aromatic and basic	YRK
Aromatic and large hydrophobic	FWYLIM
Basic	RHK
Hydrophobic	LIVMFWYA
Large hydrophobic	FLIM
Proline	P
Small	AST
Small and aliphatic	ATSVLIMQ
Small hydrophobic	AV
Small, aliphatic and aromatic	ASTVLIMQFWY

with context. While these descriptions largely follow classical textbook definitions, they also consider our own historical use and experience with peptide binding studies. For example, in our analyses we often consider the polar residue Q along with more classically defined aliphatic residues based on observed behavior in MHC peptide binding studies [15,92,93]. It is also important to note that some residues are assigned to multiple categories, as their chemical specificity is compatible with different emphases. For example, L would be considered as both aliphatic and hydrophobic. The chemical specificities defining each supertype are listed in Table 2.

#### Peptide-binding motif-based supertype assignments

As a starting point, we have largely utilized the nine supertype designations derived previously [11,12], with a few exceptions. These exceptions entail specificities that appear to be compatible with multiple superotypes. More specifically, we recognize that some alleles have repertoires overlapping both the A01 and A03 superotypes (e.g., A\*3001; see Hamdahl et al., IEDB submission 1000945 [94-96]), and others with the A01- and A24-superotypes

(e.g., A\*2902 [22]). Also, because it utilizes a non-canonical main anchor spacing, and as a result appears to have a repertoire that overlaps with other specificities, we have presently separated HLA B\*0801 and other alleles sharing sequence and serological antigen similarities, as a separate cluster. While these B\*08 alleles utilize a unique mode of peptide binding, it is likely that in most cases their repertoires overlap significantly with other superotypes, especially the B07-supertype (Sidney, Frahm, Brander and Sette, unpublished observations). As a result, we have not defined this a separate supertype.

Next, the available peptide-binding motifs were compiled. In total, 88 different class I motifs were identified. Motif information was derived from our own peptide-binding studies, or from the published scientific literature as compiled in the SYFPEITHI database [87]. The basis for each motif assignment is listed in Tables 3 and 4 for HLA-A and -B alleles, respectively. Corresponding supertype associations were assigned based on the criteria listed in Table 2.

#### Pocket analysis and supertype assignments

The amino acids comprising the B and F peptide binding pockets were compiled for all alleles for which complete sequence information was available. The positions of specific MHC residues forming the corresponding pockets are listed above. A reference panel of B and F pockets was generated to include all alleles for which the MHC-peptide binding specificity has been defined (see Tables 3 and 4). These B and F pocket structures, along with the associated alleles and corresponding binding specificity are shown in Tables 5 and 6, respectively.

Next, the B and F pocket structures of alleles whose peptide binding specificity was unknown were compared against the sequences in the reference panel. For each case, an attempt was made to find an exact match with the full set of residues in the corresponding pocket. If a match was identified, the allele was assigned the associated specificity.

**Table 2: HLA supertype specificity descriptions.**

Supertype(s)	B pocket specificity	F pocket specificity
A01	Small and aliphatic	Aromatic and large hydrophobic
A01 A03	Small and aliphatic	Aromatic and basic
A01 A24	Small, aliphatic and aromatic	Aromatic and large hydrophobic
A02	Small and aliphatic	Aliphatic and small hydrophobic
A03	Small and aliphatic	Basic
A24	Aromatic and aliphatic	Aromatic, aliphatic and hydrophobic
B07	Proline	Aromatic, aliphatic and hydrophobic
B08	Undefined	Aromatic, aliphatic and hydrophobic
B27	Basic	Aromatic, aliphatic, basic and hydrophobic
B44	Acidic	Aromatic, aliphatic and hydrophobic
B58	Small	Aromatic, aliphatic and hydrophobic
B62	Aliphatic	Aromatic, aliphatic and hydrophobic

**Table 3: HLA-A motif/structure reference panel alleles.**

Allele	Basis for motif	Supertype association
A*0101	Binding assay	A01
A*0201	Binding assay	A02
A*0202	Binding assay	A02
A*0203	Binding assay	A02
A*0204	Pool sequencing/ligand elution	A02
A*0205	Binding assay	A02
A*0206	Binding assay	A02
A*0207	Binding assay	A02
A*0214	Pool sequencing/ligand elution	A02
A*0217	Pool sequencing/ligand elution	A02
A*0301	Binding assay	A03
A*1101	Binding assay	A03
A*2301	Binding assay	A24
A*2402	Binding assay	A24
A*2601	Binding assay	A01
A*2602	Pool sequencing/ligand elution	A01
A*2603	Pool sequencing/ligand elution	A01
A*2902	Binding assay	A01 A24
A*3001	Binding assay	A01 A03
A*3002	Binding assay	A01
A*3003	Pool sequencing/ligand elution	A01
A*3004	Pool sequencing/ligand elution	A01
A*3101	Binding assay	A03
A*3201	Binding assay	A01
A*3301	Binding assay	A03
A*3303	Published motif	A03
A*6601	Pool sequencing/ligand elution	A03
A*6801	Binding assay	A03
A*6802	Binding assay	A02
A*6901	Pool sequencing/ligand elution	A02
A*7401	Binding assay	A03

city shown in Tables 5 and 6. If an exact match could not be found, then a match with a key residue sequence was attempted. If no match was identified, the allele was considered unassigned. For each allele where a match for the full or, secondarily, key residue sequence could be identified for both the B and F pockets with any of the alleles indicated in Tables 3 and 4, a corresponding HLA supertype was assigned.

Of the 945 sequences analyzed, matches at both B and F pockets were found for 764 (80.8%) (Table 7). Notably, for the majority (57%) of alleles not in the reference panel full sequence matches were identified at both the B and F pockets. Figures 1 and 2 indicate the alleles associated with each HLA-A or -B supertype, respectively. Conversely, as an index, Additional file 1 provides the supertype assignment for each of the 945 HLA-A and -B alleles examined, along with their respective B and F pocket structures.

At the HLA-A locus, alleles were fairly evenly distributed amongst the four superotypes we have defined. Considering the alleles with broad, or dual, specificity (i.e., those assigned as A01-A03 or A01-A24), the minimum was 57

**Table 4: HLA-B motif/structure reference panel alleles.**

Allele	Basis for motif	Supertype association
B*0702	Binding assay	B07
B*0703	Pool sequencing/ligand elution	B07
B*0705	Pool sequencing/ligand elution	B07
B*0801	Binding assay	B08
B*0802	Pool sequencing/ligand elution	B08
B*1402	Pool sequencing/ligand elution	B27
B*1501	Binding assay	B62
B*1502	Pool sequencing/ligand elution	B62
B*1503	Binding assay	B27
B*1508	Pool sequencing/ligand elution	B07
B*1509	Pool sequencing/ligand elution	B27
B*1510	Pool sequencing/ligand elution	B27
B*1512	Pool sequencing/ligand elution	B62
B*1513	Pool sequencing/ligand elution	B62
B*1516	Pool sequencing/ligand elution	B58
B*1517	Pool sequencing/ligand elution	B58
B*1518	Pool sequencing/ligand elution	B27
B*1801	Binding assay	B44
B*2702	Pool sequencing/ligand elution	B27
B*2703	Pool sequencing/ligand elution	B27
B*2704	Pool sequencing/ligand elution	B27
B*2705	Binding assay	B27
B*2706	Pool sequencing/ligand elution	B27
B*2707	Pool sequencing/ligand elution	B27
B*2709	Pool sequencing/ligand elution	B27
B*3501	Binding assay	B07
B*3503	Pool sequencing/ligand elution	B07
B*3701	Pool sequencing/ligand elution	B44
B*3801	Pool sequencing/ligand elution	B27
B*3901	Pool sequencing/ligand elution	B27
B*3902	Pool sequencing/ligand elution	B27
B*3909	Pool sequencing/ligand elution	B27
B*4001	Binding assay	B44
B*4002	Binding assay	B44
B*4006	Pool sequencing/ligand elution	B44
B*4201	Binding assay	B07
B*4402	Binding assay	B44
B*4403	Binding assay	B44
B*4501	Binding assay	B44
B*4601	Pool sequencing/ligand elution	B62
B*4801	Pool sequencing/ligand elution	B27
B*5101	Binding assay	B07
B*5102	Pool sequencing/ligand elution	B07
B*5103	Pool sequencing/ligand elution	B07
B*5201	Pool sequencing/ligand elution	B62
B*5301	Binding assay	B07
B*5401	Binding assay	B07
B*5501	Pool sequencing/ligand elution	B07
B*5502	Pool sequencing/ligand elution	B07
B*5601	Pool sequencing/ligand elution	B07
B*5701	Binding assay	B58
B*5702	Pool sequencing/ligand elution	B58
B*5801	Binding assay	B58
B*5802	Binding assay	B58
B*6701	Pool sequencing/ligand elution	B07
B*7301	Pool sequencing/ligand elution	B27
B*7801	Pool sequencing/ligand elution	B07

**Table 5: B pocket structures of reference panel alleles.**

Residues <sup>1</sup>	Key residues	Reference panel allele(s)	Associated supertype(s)	Specificity
YDSVENIFNY	DENIFNY	B*0801-2	B08	Undefined
YFAVMEKVHC	FMEKVHC	A*0207	A02	Small and aliphatic
YFAVMEKVHF	FMEKVHF	A*0217	A02	Small and aliphatic
YFAVMEKVHY	FMEKVHY	A*0201-4	A02	Small and aliphatic
YFAVMENMHY	FMENMHY	A*0101	A01	Small and aliphatic
YFAVMENVHY	FMENVHY	A*3201, A*7401	A01 A03	Small and aliphatic
YFAVMENVQY	FMENVQY	A*0301	A03	Small and aliphatic
YHSVTEISNS	HTEISNS	B*3701	B44	Acidic
YHSVTNISNY	HTNISNY	B*1801	B44	Acidic
YHTVEEICKY	HEEICKY	B*2702-7, B*2709	B27	Basic
YHTVENICKY	HENICKY	B*7301	B27	Basic
YHTVKEISNY	HKEISNY	B*4001-2, B*4006, B*4501	B44	Acidic
YSAVMEKVHF	SMEKVHF	A*2301, A*2402	A24	Aromatic and aliphatic
YSAVMENVHY	SMENVHY	A*3002-4	A01	Small and aliphatic
YSAVMENVQY	SMENVQY	A*3001	A01 A03	Small and aliphatic
YTAVMENVHY	TMENVHY	A*3101	A03	Small and aliphatic
YTAVMNNVHY	TMNNVHY	A*3301, A*3303	A03	Small and aliphatic
YTAVMQNVQY	TMQNVQY	A*2902	A01 A24	Small, aliphatic and aromatic
YYAVENIYQY	YENIYQY	B*5501-2, B*5601	B07	Proline
YYAVGNIYQY	YGNIIYQY	B*5401	B07	Proline
YYAVMEISNY	YMEISNY	B*1501, B*1512	B62	Aliphatic
YYAVMEKVHY	YMEKVHY	A*0205, A*0206, A*0214	A02	Small and aliphatic
YYAVMEKYQY	YMEKYQY	B*4601	B62	Aliphatic
YYAVMENMSY	YMENMSY	B*1516-17, B*5701-2	B58	Small
YYAVMENVQY	YMENVQY	A*1101	A03	Small and aliphatic
YYAVMNIFNY	YMNIFNY	B*1508	B07	Proline
YYAVMNISNY	YMNISNY	B*1502, B*1513	B62	Aliphatic
YYAVMNNVHY	YMNNVHY	A*2601-3	A01	Small and aliphatic
YYAVMNNVQY	YMNNVQY	A*6601, A*6801-2, A*6901	A02 A03	Small and aliphatic
YYAVTEISNY	YTEISNY	B*5201	B62	Aliphatic
YYAVTENMSY	YTENMSY	B*5801-2	B58	Small
YYAVTNIFNY	YTNIFNY	B*3501, B*3503, B*5101-3, B*5301, B*7801	B07	Proline
YYSVEEISNY	YEEISNY	B*1503, B*3902, B*4801	B27	Basic
YYSVENICNS	YENICNS	B*3909	B27	Basic
YYSVENICNY	YENICNY	B*1402, B*1509-10, B*1518, B*3801, B*3901	B27	Basic
YYSVENIYNY	YENIYNY	B*0703	B07	Proline
YYSVENIYQY	YENIYQY	B*0702, B*0705, B*4201, B*6701	B07	Proline
YYTVKEISNY	YKEISNY	B*4402-3	B44	Acidic

1. Based on data presented in Saper et al, and Madden (see Methods), the MHC residues utilized as constituting the B pocket are: 7, 9, 24, 34, 45, 63, 66, 67, 70, and 99. Key residues are those in positions 9, 45, 63, 66, 67, 70, and 99.

alleles for A24, and the maximum was 95 alleles for A03. 75 alleles were assigned to the A02 supertype, and 80 to the A01 supertype. At the HLA-B locus, the B07-supertype is the largest, with 165 members. 19 alleles were associated with the B08 pattern. As noted above, we hypothesize that alleles in this cluster will likely cross-react with other superotypes (especially B07), so we do not consider this group as a distinct supertype. The B58 supertype was assigned only 22 alleles, making it the smallest supertype.

**Novel superotypes could not be identified, but several alleles have specificities spanning two different superotypes**

From Tables 5 and 6, it is evident that not all possible combinations of B and F pocket specificities are present within the reference panel. For example, there are no alle-

les associated with a preference for acidic residues in position 2 and basic residues at the C-terminus. Hence, we were interested to see if combinations not found in the original supertype assignments were revealed in the present analysis. Interestingly, we did not identify any new combinations. It is possible that new specificities will be identified from amongst the set of 181 alleles for which pocket matches could not be obtained. However, we also note that in the majority of these cases, matches could be made if one allowed a single conservative residue change (e.g., E to D). Thus, based on the analyses done to date, it would appear that the set of supertype specificities currently identified will cover virtually all HLA-A and -B class I MHC alleles.

**Table 6: F pocket structures of reference panel alleles.**

Residues <sup>1</sup>	Key residues <sup>2</sup>	Reference panel allele(s)	Associated supertype(s)	Specificity
DDTLYIIIEHYWTKW	DTLH	A*3001	A01 A03	Aromatic and basic
DDTLYIIRDYWTKW	DTLD	A*0301, A*1101	A03	Basic
DDTLYIMQDYWTKW	DTLD	A*3101, A*3301, A*3303, A*7401	A03	Basic
DDTLYIMRDYWTKW	DTLD	A*6801	A03	Basic
DDTLYIRHYWTKW	DTLY	A*6802	A02	Aliphatic
DDTLYIRQDYWTKW	DTLD	A*6601	A03	Basic
DDTLYLNHDYWTKW	DTLD	B*2703, B*2705	B27	Hydrophobic and basic
DDTLYLNHHYWTKW	DTLH	B*2709	B27	Large hydrophobic
DDTLYLSNYYWTKW	DTLY	B*2707	B27	Large hydrophobic
DDTLYVRHYWTKW	DTLY	A*6901	A02	Aliphatic
DGNLYWTNIFYWTKW	GNLF	B*7301	B27	Large hydrophobic
DNIAYLMHYWTKW	NIAY	A*2301, A*2402	A24	Large hydrophobic
DNIAYLNHDYWTKW	NIAD	B*2702	B27	Large hydrophobic
DNTAYLSNYYWTKW	NTAY	B*0802	B08	Hydrophobic
DNTLYIIIEHYWTKW	NTLH	A*3002-4	A01	Aromatic
DNTLYIIRDYWTKW	NTLD	A*0101	A01	Aromatic
DNTLYIMRDYWTKW	NTLD	A*2902	A01 A24	Aromatic and large hydrophobic
DNTLYIRQDYWTKW	NTLD	A*2601	A01	Aromatic
DNTLYIRQNYWTKW	NTLN	A*2602	A01	Aromatic
DSIAYIMQDYWTKW	SIAD	A*3201	A01	Aromatic
DSNLYLRDSYWTKW	SNLS	B*4601	B62	Large hydrophobic
DSNLYLRNFYWTKW	SNLF	B*3901-2, B*3909, B*6701	B07 B27	Hydrophobic
DSNLYLSDYYWTKW	SNLY	B*0702-3	B07	Hydrophobic
DSNLYLSNYYWTKW	SNLY	B*0705, B*0801, B*4201	B07	Hydrophobic
DSNLYLWNFYWTKW	SNLF	B*1402	B27	Hydrophobic
DSNLYWTNLYWTKW	SNLL	B*5401, B*5501-2, B*5601	B07	Small hydrophobic
DSNLYWTNYYWTKW	SNLY	B*7801	B07	Hydrophobic
DSTLYLNDYYWTKW	STLY	B*2706	B27	Large hydrophobic
DSTLYLNHDYWTKW	STLD	B*2704	B27	Large hydrophobic
HDTLYIRQDYWTKW	DTLD	A*2603	A01	Aromatic
HDTLYLMHYWTKW	DTLY	A*0217	A02	Aliphatic
HDTLYLRHYWTKW	DTLY	A*0202, A*0205, A*0214	A02	Aliphatic
HDTLYVMHYWTKW	DTLY	A*0204	A02	Aliphatic
HDTLYVRHYWTKW	DTLY	A*0201, A*0203, A*0206-7	A02	Aliphatic
YDTLYIRNFYWTKW	DTLF	B*3701	B44	Hydrophobic
YNIAIIRDSYWTKW	NIAS	B*1513, B*5301, B*5801	B07 B58 B62	Large hydrophobic
YNIAIYVDSYWTKW	NIAS	B*5701	B58	Large hydrophobic
YNIAIYNYYWTKW	NIAY	B*5702	B58	Large hydrophobic
YNIAYLNRHDYWTKW	NIAD	B*1517	B58	Large hydrophobic
YNIAYLRFYWTKW	NIAF	B*3801	B27	Large hydrophobic
YNIAYLWDSYWTKW	NIAS	B*5802	B58	Large hydrophobic
YNIAYWRDSYWTKW	NIAS	B*1516	B58	Large hydrophobic
YNIAYWTNYYWTKW	NIAY	B*5101-3, B*5201	B07 B62	Large hydrophobic
YNTAYIRDDYWTKW	NTAD	B*4402-3	B44	Hydrophobic
YSNLYIRDFYWTKW	SNLF	B*3503	B07	Hydrophobic
YSNLYIRDSYWTKW	SNLS	B*1502, B*3501	B07 B62	Hydrophobic
YSNLYLRDSYWTKW	SNLS	B*1501, B*1503, B*1508, B*1512, B*1518, B*1801	B07 B27 B44 B62	Large hydrophobic
YSNLYLRDYYWTKW	SNLY	B*1510	B27	Hydrophobic
YSNLYLRNYYWSKL	SNLY	B*4001	B44	Hydrophobic
YSNLYLRNYYWTKW	SNLY	B*1509	B27	Hydrophobic
YSNLYLSNYYWSKL	SNLY	B*4801	B27	Hydrophobic
YSNLYLSNYYWTKW	SNLY	B*4002	B44	Hydrophobic
YSNLYWRNLYWTKW	SNLL	B*4501	B44	Small hydrophobic
YSNLYWTNYYWTKW	SNLY	B*4006	B44	Hydrophobic

1. Based on data presented in Saper et al, and Madden (see Methods), the MHC residues utilized as constituting the F pocket are: 74, 77, 80, 81, 84, 95, 97, 114, 116, 123, 133, 143, 146, and 147. Key residues are those in positions 77, 80, 81, and 116.

2. The key residue pockets DTLH, DTLN and DTLY are each associated with two different, although overlapping, specificity descriptions. In each case, one description is associated with HLA B27 alleles, and in the other with HLA A alleles. In assigning key residue matches, matches were assigned on the basis of corresponding locus.

**Table 7: Quantification of supertype assignments.**

Supertype	(n)	Classification criteria				
		Binding assay	Pool sequencing or ligand elution	Full sequence match at B and F	I full and I key sequence match	Key residue match at B and F
A01	61	4	4	42	11	0
A01 A03	9	1	0	4	4	0
A01 A24	10	1	0	8	1	0
A02	75	7	4	57	7	0
A03	86	6	2	68	10	0
A24	47	2	0	36	9	0
B07	165	6	11	96	52	0
B08	19	1	1	13	4	0
B27	98	2	16	52	27	1
B44	108	6	2	57	43	0
B58	22	3	3	12	4	0
B62	64	1	5	44	12	2
Unassigned	181	-	-	-	-	-
<b>Total</b>	<b>945</b>	<b>40</b>	<b>48</b>	<b>489</b>	<b>184</b>	<b>3</b>

In addition to A\*2902 and A\*3001, the present analysis has identified 17 alleles expected to have a specificity overlapping two supertypes. Nine alleles matched pocket preference patterns that would be compatible with both the A01- and A03-supertypes, and another 10 with the A01- and A24-supertypes. In the former case, the association was established on the basis of pocket matches with A\*3001. Not surprisingly, several, but not all, of the alleles assigned the A01-A03 specificity also share the A30 antigen. The A01-A24 cross-reactivity pattern was established on the basis of pocket matches with A\*2902. All of the alleles associated with the A01-A24 pattern also shared the A29 antigen.

#### Unexpected supertype assignments

Typically, the supertype assignment for a particular allele follows the predominant assignment for other alleles sharing the same serological antigen. With this in mind, we did identify several instances where the current classification differed from what was expected based on serology or previous classification (Table 8). Of these, the more striking ones involve alleles for which the assigned supertype represents a non-conservative change in the binding specificity from what would have been expected. For example, A\*0265 and A\*0280, which are associated with the A02 serological antigen, and thus might be expected to have an F pocket specificity for hydrophobic/aliphatic residues, were found to have an F pocket matching that of A03 supertype alleles, which have a specificity for positively charged residues. Similarly, B\*4012 and B\*4440 were found to have B27 supertype B pockets, associated with a preference for positively charged residues, when a B44 supertype specificity for acidic residues might have been expected.

As noted above, in the present analysis, and contrary to what was done in the original analysis, we did not make supertype assignments for alleles without an exact or key match by considering conservative substitutions. As a result of this more conservative approach, we now no longer assign supertypes to some alleles previously given a supertype designation (Table 9). In the majority of these cases, however, the original designation would still seem to be a reasonable assumption.

#### Discussion

In the present study we have attempted to classify almost 1000 HLA-A and -B class I alleles into supertypes. This is nearly a 10-fold increase in the number of alleles compared to our original classification done about a decade ago [12]. Besides providing supertype assignments for considerably more alleles, the present report has attempted to make more transparent how the original "phenomenological" classifications were done. About 80% of the 945 alleles examined were classified into one of the nine supertypes identified previously. Analysis of B and F pocket specificity patterns did not suggest the existence of any novel supertypes.

HLA supertypes do not necessarily demarcate groups of alleles with completely non-overlapping repertoires. A binding repertoire overlapping multiple supertypes has been demonstrated previously, for example, in the cases of A\*2902 [22] and A\*3001 (see Hamdahl et al., IEDB submission 1000945 [94-96]). In the present study we have identified 17 other alleles that would appear to have specificities that bridge either the A01 and A03 supertypes, or the A01 and A24 supertypes. At the same time, individual peptides can be readily identified that bear a



HLA A-supertypes									
A*01									
A*0101	A*0103	A*0112	A*2609	A*2618	A*3012	A*3602	A*2501	A*3603	
A*2601	A*0104	A*0114	A*2610	A*2619	A*3202	A*3604	A*2502	A*7410	
A*2602	A*0106	A*0115	A*2611	A*2621	A*3205		A*2504	A*8001	
A*2603	A*0107	A*2604	A*2612	A*2623	A*3206		A*2622		
A*3002	A*0108	A*2605	A*2613	A*2624	A*3207		A*3110		
A*3003	A*0109	A*2606	A*2614	A*2626	A*3209		A*3203		
A*3004	A*0110	A*2607	A*2615	A*3006	A*3210		A*3204		
A*3201	A*0111	A*2608	A*2617	A*3009	A*3601		A*3208		
A*01 A*03									
A*3001	A*3008	A*3011	A*3014	A*3015			A*0252	A*3013	A*6806 A*6807
A*01 A*24									
A*2902	A*2901	A*2905	A*2909	A*2911			A*2913		
	A*2903	A*2906	A*2910	A*2912					
A*02									
A*0201	A*0209	A*0224	A*0240	A*0257	A*0271	A*6827	A*0241		
A*0202	A*0211	A*0225	A*0243	A*0258	A*0272	A*6828	A*0242		
A*0203	A*0212	A*0226	A*0244	A*0259	A*0274		A*0250		
A*0204	A*0213	A*0227	A*0245	A*0261	A*0275		A*0260		
A*0205	A*0215	A*0228	A*0246	A*0262	A*0277		A*0273		
A*0206	A*0216	A*0230	A*0247	A*0263	A*0278		A*0284		
A*0207	A*0218	A*0231	A*0248	A*0266	A*0279		A*6815		
A*0214	A*0219	A*0236	A*0249	A*0267	A*0282				
A*0217	A*0220	A*0237	A*0251	A*0268	A*0283				
A*6802	A*0221	A*0238	A*0254	A*0269	A*0285				
A*6901	A*0222	A*0239	A*0256	A*0270	A*0286				
A*03									
A*0301	A*0302	A*0316	A*1112	A*3105	A*3404	A*6812	A*7402	A*0265	
A*1101	A*0304	A*0317	A*1113	A*3106	A*3406	A*6813	A*7403	A*0280	
A*3101	A*0305	A*1102	A*1114	A*3109	A*6602	A*6814	A*7404	A*0309	
A*3301	A*0306	A*1103	A*1115	A*3111	A*6603	A*6816	A*7405	A*1106	
A*3303	A*0307	A*1104	A*1116	A*3304	A*6604	A*6819	A*7407	A*1122	
A*6601	A*0308	A*1105	A*1120	A*3305	A*6803	A*6821	A*7408	A*3112	
A*6801	A*0310	A*1107	A*1121	A*3306	A*6804	A*6822	A*7409	A*6805	
A*7401	A*0312	A*1108	A*1123	A*3307	A*6808	A*6824	A*7411	A*6820	
	A*0313	A*1109	A*3103	A*3402	A*6809	A*6825		A*6823	
	A*0314	A*1110	A*3104	A*3403	A*6810	A*6826		A*7406	
A*24									
A*2301	A*2302	A*2310	A*2410	A*2422	A*2433	A*2440	A*2305	A*2442	
A*2402	A*2303	A*2403	A*2411	A*2423	A*2434	A*2443	A*2312	A*2444	
	A*2304	A*2405	A*2413	A*2426	A*2435	A*2446	A*2417	A*2452	
	A*2306	A*2406	A*2418	A*2427	A*2437	A*2447	A*2425		
	A*2307	A*2408	A*2420	A*2428	A*2438	A*2448	A*2430		
	A*2308	A*2409	A*2421	A*2429	A*2439	A*2449	A*2441		
Unclassified									
A*0102	A*0233	A*0276	A*1118	A*2414	A*2432	A*2616	A*3007	A*3308	
A*0113	A*0234	A*0281	A*1119	A*2415	A*2450	A*2620	A*3010	A*3401	
A*0208	A*0235	A*0315	A*2309	A*2419	A*2451	A*2904	A*3102	A*3405	
A*0210	A*0255	A*1111	A*2404	A*2424	A*2453	A*2907	A*3107	A*4301	
A*0229	A*0264	A*1117	A*2407	A*2431	A*2503	A*2914	A*3108	A*6817	

**Figure 1**

**Supertype classification of HLA-A alleles.** The alleles associated with each HLA-A supertype, multiple supertypes, or that are unclassified, are shown. Under each supertype, alleles are group (by color) on the basis of the stringency of selection: experimentally established motif (i.e., reference panel) (green), exact match(es) in the B and F pockets (white), one exact and one key residue pocket match (yellow), key residue match(es) at B and F pockets (grey). Alleles with no match at one or both pockets are listed with red font.

particular supermotif, but that do not bind individual HLA allele members of the supertype, or that bind alleles of other supertypes, even supertypes associated with a different locus. Typically, in the first case, these phenomena result from differences in motif compatibility, perhaps at secondary positions. The second case likely reflects overlap(s) between the supertypes in terms of specificity, although in rare cases binding can be accomplished when no main anchor motif compatibility is apparent.

These observations are exemplified by a large scale analysis of the capacity of a non-redundant set of 252 known EBV and HIV derived epitopes to bind a panel of 30 different HLA class I A and B molecules (Sidney, Frahm,

Brander and Sette, unpublished observations). It was found that about 21% of the peptides bearing a specific supermotif bound a given allele in the corresponding supertype with an affinity of 100 nM, or better. By contrast, only in 1% of the cases considered did an allele bind a peptide that did not have the corresponding supermotif. At the same time, it was noted that in the set of peptides utilized 62% (155/252) have motifs associated with 2 or more supertypes. The pattern of binding also followed this general promiscuity. It is also significant to note that when the same library of peptides was examined for recognition in HIV/EBV patients, it was found that ~95% of the epitopes were recognized in individuals not expressing the allele the epitope was originally reported to be

HLA B-supertypes											
Bo7											
B*0702	B*0704	B*0741	B*3540	B*5109	B*5134	B*5510		B*0707	B*3518	B*5112	B*8102
B*0703	B*0706	B*0742	B*3541	B*5110	B*5135	B*5515		B*0709	B*3529	B*5113	
B*0705	B*0715	B*0743	B*3542	B*5111	B*5136	B*5517		B*0712	B*3530	B*5114	
B*1508	B*0719	B*3507	B*3543	B*5116	B*5138	B*5519		B*0714	B*3534	B*5120	
B*3501	B*0720	B*3508	B*3544	B*5117	B*5302	B*5603		B*0716	B*3537	B*5137	
B*3503	B*0721	B*3511	B*3545	B*5118	B*5306	B*5605		B*0717	B*3539	B*5304	
B*4201	B*0722	B*3514	B*3546	B*5119	B*5308	B*5613		B*0718	B*3551	B*5508	
B*5101	B*0724	B*3515	B*3554	B*5121	B*5310	B*5615		B*0723	B*3553	B*5511	
B*5102	B*0725	B*3521	B*3555	B*5123	B*5403	B*5616		B*0736	B*3558	B*5513	
B*5103	B*0726	B*3522	B*3557	B*5124	B*5404	B*7802		B*0737	B*3560	B*5514	
B*5301	B*0730	B*3524	B*3561	B*5126	B*5406	B*7804		B*3502	B*3806	B*5602	
B*5401	B*0731	B*3531	B*3910	B*5128	B*5407			B*3504	B*3807	B*5604	
B*5501	B*0733	B*3532	B*3916	B*5129	B*5503			B*3505	B*3917	B*5609	
B*5502	B*0734	B*3533	B*4204	B*5130	B*5504			B*3506	B*4206	B*5610	
B*5601	B*0735	B*3535	B*4205	B*5131	B*5505			B*3509	B*4406	B*5611	
B*6701	B*0739	B*3536	B*5105	B*5132	B*5507			B*3512	B*5104	B*5612	
B*7801	B*0740	B*3538	B*5108	B*5133	B*5509			B*3517	B*5106	B*8101	
Bo8											
B*0801	B*0807	B*0811	B*0815	B*0819	B*0821	B*0823	B*0825	B*0803	B*0812		
B*0802	B*0809	B*0813	B*0818	B*0820	B*0822	B*0824		B*0808	B*0816		
B27											
B*1402	B*1401	B*1593	B*3926					B*1405	B*3913		B*5518
B*1503	B*1403	B*1598	B*3927					B*1523	B*3915		
B*1509	B*1406	B*1599	B*3929					B*1568	B*3924		
B*1510	B*1407	B*2710	B*3930					B*2701	B*3928		
B*1518	B*1537	B*2713	B*3932					B*2711	B*3933		
B*2702	B*1547	B*2715	B*4012					B*2714	B*3934		
B*2703	B*1549	B*2717	B*4802					B*2719	B*4440		
B*2704	B*1551	B*2725	B*4803					B*2720	B*4807		
B*2705	B*1552	B*2728	B*4804					B*2721	B*4808		
B*2706	B*1554	B*3805	B*4805					B*2724			
B*2707	B*1561	B*3809	B*4809					B*2727			
B*2709	B*1562	B*3810	B*4810					B*2730			
B*3801	B*1569	B*3811	B*4811					B*3526			
B*3901	B*1572	B*3904	B*4812					B*3903			
B*3902	B*1574	B*3907	B*4813					B*3905			
B*3909	B*1580	B*3914	B*9503					B*3906			
B*4801	B*1590	B*3918						B*3908			
B*7301	B*1591	B*3923						B*3911			
B44											
B*1801	B*1553	B*1820	B*4029	B*4056	B*4422	B*4435	B*5001	B*1546	B*4028	B*4048	B*4420
B*3701	B*1803	B*3704	B*4035	B*4057	B*4424	B*4436	B*5002	B*1802	B*4030	B*4051	B*4425
B*4001	B*1805	B*4005	B*4039	B*4102	B*4426	B*4437	B*5004	B*1814	B*4033	B*4052	B*4431
B*4002	B*1806	B*4011	B*4040	B*4103	B*4427	B*4438		B*4003	B*4034	B*4058	B*4434
B*4006	B*1810	B*4014	B*4049	B*4404	B*4428	B*4503		B*4004	B*4036	B*4059	B*4439
B*4402	B*1811	B*4015	B*4050	B*4407	B*4429	B*4504		B*4009	B*4038	B*4101	B*4441
B*4403	B*1813	B*4016	B*4053	B*4413	B*4430	B*4505		B*4010	B*4042	B*4104	B*4442
B*4501	B*1815	B*4020	B*4054	B*4416	B*4432	B*4507		B*4018	B*4043	B*4106	B*4502
	B*1819	B*4026	B*4055	B*4421	B*4433	B*4904		B*4019	B*4044	B*4107	B*4704
								B*4023	B*4045	B*4405	B*4705
								B*4024	B*4047	B*4414	
B58											
B*1516	B*1567	B*5804						B*5704			
B*1517	B*1595	B*5806						B*5705			
B*3701	B*5703	B*5807						B*5706			
B*3702	B*5707	B*5808						B*5805			
B*5801	B*5708	B*5809									
B*5802	B*5709	B*5811									
B62											
B*1501	B*1505	B*1530	B*1548	B*1578	B*1596	B*5202	B*9502	B*1504	B*1558		B*1309
B*1502	B*1514	B*1531	B*1550	B*1581	B*1597	B*5203	B*9504	B*1507	B*1573		B*1313
B*1512	B*1515	B*1533	B*1560	B*1582	B*3528	B*5204		B*1524	B*1586		
B*1513	B*1519	B*1534	B*1563	B*1583	B*4021	B*5205		B*1535	B*4408		
B*4601	B*1520	B*1538	B*1565	B*1585	B*4603	B*5207		B*1542	B*4602		
B*5201	B*1525	B*1539	B*1570	B*1588	B*4604	B*5208		B*1545			
	B*1528	B*1540	B*1575	B*1592	B*4605	B*7805		B*1555			
Unclassified											
B*0708	B*0806	B*1310	B*1543	B*1589	B*2723	B*3547	B*3709	B*4008	B*4410	B*4901	B*5402
B*0710	B*0810	B*1311	B*1544	B*1804	B*2726	B*3548	B*3802	B*4013	B*4411	B*4902	B*5405
B*0711	B*0814	B*1312	B*1556	B*1807	B*2729	B*3549	B*3803	B*4025	B*4412	B*4903	B*5512
B*0713	B*0817	B*1404	B*1557	B*1808	B*3510	B*3550	B*3804	B*4027	B*4415	B*5107	B*5516
B*0727	B*1301	B*1506	B*1564	B*1809	B*3513	B*3552	B*3808	B*4037	B*4417	B*5115	B*5606
B*0728	B*1302	B*1511	B*1566	B*1812	B*3516	B*3556	B*3912	B*4046	B*4418	B*5122	B*5607
B*0729	B*1303	B*1521	B*1571	B*1818	B*3519	B*3702	B*3919	B*4060	B*4506	B*5206	B*5608
B*0732	B*1304	B*1527	B*1576	B*2708	B*3520	B*3705	B*3920	B*4061	B*4701	B*5303	B*5614
B*0738	B*1306	B*1529	B*1577	B*2712	B*3523	B*3706	B*3922	B*4105	B*4702	B*5305	B*5901
B*0804	B*1307	B*1532	B*1584	B*2716	B*3525	B*3707	B*3931	B*4202	B*4703	B*5307	B*6702
B*0805	B*1308	B*1536	B*1587	B*2718	B*3527	B*3708	B*4007	B*4409	B*4806	B*5309	B*7803

**Figure 2**  
**Supertype classification of HLA-B alleles.** The alleles associated with each HLA-B supertype, multiple supertypes, or that are unclassified, are shown. Under each supertype, alleles are grouped (by color) on the basis of the stringency of selection as described in the legend to Figure 1.

**Table 8: Unexpected and/or revised supertype assignments.**

Allele	Supertype assignment	
	Expected <sup>1</sup> or previous	Current
A*0252	A02	A01 A03
A*0265	A02	A03
A*0280	A02	A03
A*3001	A24	A01 A03
A*3002	A24	A01
A*3003	A24	A01
A*3110	A03	A01
A*7410	A03	A01
B*3528	B07	B62
B*3806	B27	B07
B*3807	B27	B07
B*3910	B27	B07
B*3916	B27	B07
B*3917	B27	B07
B*4012	B44	B27
B*4021	B44	B62
B*4406	B44	B07
B*4408	B44	B62
B*4440	B44	B27
B*5518	B07	B27

1. Expected based on serological association.

restricted by, and the promiscuity more often than not involved an allele outside of the supertype associated with originally described restricting allele [97]. Thus, it is apparent that the lines of demarcation between super-types can be fuzzy from the perspective of both the allelic specificity and the peptide motif.

Restriction outside or across superotypes can also originate from overlaps in supermotifs (e.g., A02 and B62), or for alleles such as B\*0801 which do not utilize the typical P2/ Cterminus anchor spacing. B\*0801 utilizes P3 and P5, not P2, and as such may be compatible with several super-types and alleles. Thus, an A02- or A24-supertype epitope cross-reacting with B\*0801 is not an example of a motif "failure", but merely reflects the fact that the specific peptide has both motifs.

It is important to emphasize that superotypes are based on MHC binding, and that MHC binding alone is not sufficient criteria for T cell recognition. Indeed, hundreds of examples of peptides that bind with remarkably high affinity, but that are not recognized by T cells, have been reported in the literature. We note that even in the best affinity ranges (i.e., IC<sub>50</sub> <10 nM), rarely more than 10% of the peptides can be expected to be recognized [98]. Similarly, binding affinity is not necessarily correlative of frequency of recognition [99]. It is true that the trend is towards the most frequently recognized peptides being also the highest affinity binders [38,50,100], but that is not always the case, and there are clearly cases where the dominant epitope has an IC<sub>50</sub> of ~100 nM, while several other non-recognized peptides have affinities in the <10 nM range.

It must also be emphasized that membership of an epitope in a supertype is not sufficient to guarantee its recognition by T cells in the context of different MHC alleles. Peptide binding to MHC is an absolute requirement for an epitope to be recognized by T cells. At the same time, many other factors, including protein expression and processing, as well as T cell repertoire and the specific

**Table 9: Alleles reclassified as "unassigned".**

Allele	Previous assignment	B pocket match	F pocket match	Comments
A*0102	A01	-	A01 full	Single difference with A*0101 (F to S) at position 9 in B pocket is non-conservative.
A*2404	A24	A24 full	-	F pocket key sequence is similar to A02 and B27 (hydrophobic), so A24 is still likely.
A*3401	A03	-	A03 full	N/K in 63/66 are relatively unique, otherwise similar to A03 in the B pocket.
A*4301	A01	-	A01 full	Q to N in 63 is only difference with A*2601, so A01 is still likely.
B*1301	B62	B62 key	-	Unusual F pocket.
B*1302	B62	B62 key	-	Unusual F pocket.
B*1506	B62	-	B07 B27 B44 B62 full	Single conservative change (Y to F) at position 99 of B pocket, compared to B*1501; B62 still likely.
B*1521	B62	-	B07 B62 full	S to C change in position 67 is the only B pocket difference with B*1501, so B62 is still likely.
B*2708	B27	B27 full	-	Position 77 T to N change is only difference with B*2704, so B27 is still likely.
B*3802	B27	B27 full	-	I to T in position 80 of the F pocket is the only difference with B*3801, so B27 is still likely.
B*4701	B44	-	B27 key	Y to F at position 99 is the only difference with B*4402-3 in the B pocket, so B44 is still likely.
B*4901	B44	B44 full	-	F full pocket is similar to B*3801 (hydrophobic), so B44 is still likely.

MHC context, come into play in determining whether a peptide will be an epitope or not, or whether an epitope will be promiscuously recognized within a specific supertype. For example, Goulder and co-workers, studying B7-supertype epitopes, found that differential selection pressure exerted on HIV by CTL targeting identical epitopes, but restricted by distinct HLA alleles from the same supertype, can result in significant functional differences [101]. Macdonald et al., looking at two B44 subtypes described as members of the HLA B44-supertype, reported that a naturally selected dimorphism between the two molecules alters class I structure, peptide repertoire, and T cell recognition [102].

The intent of the current study was to derive an updated classification of HLA class I MHC alleles on the basis of primary anchor specificity. For the vast majority of HLA class I molecules whose binding specificity have been described by crystal structure, pool sequencing or peptide binding studies, the main anchor interactions of the peptide almost invariably involve the MHC B and F pockets, while other pockets likely dictate secondary interactions. This pattern also appears to be true for most macaque and chimpanzee class I alleles studied to date.

There are exceptions, however, and indeed we have not assigned B\*08 alleles to a specific supertype in recognition of the fact that these alleles appear to utilize pockets other than the B pocket as a primary anchor contact. For HLA class I molecules in general, the B and F pockets are the most likely main anchor contacts, while other pockets likely dictate secondary interactions. High levels of cross-reactivity have been experimentally demonstrated in the case of 6 superotypes for alleles that vary at secondary pockets [15,17,20-22].

By contrast, in the murine system it is well recognized that other pockets are often the important primary peptide contacts [103-109]. Thus, to utilize the classification approach described here in the context of other species, additional pockets may need to be considered. It is also likely that the further parsing or sub-classifying of superotypes on the basis of secondary interactions can be accomplished.

In the case of HLA-B alleles, F pocket specificity is difficult to correlate with a specific sequence, as a diverse pattern of residues appears to be associated with similar binding specificity. Independent of the residues in the F pocket, most HLA-B alleles seem to bind hydrophobic residues. Thus, assignment of B alleles was primarily driven by the specificity exhibited by the B pocket. On the other hand, it is also possible that greater resolution in the F pocket could be achieved as more data become available to discriminate different preference patterns. For example, in

the B7 supertype it is apparent that some alleles, like B\*3501, prefer large hydrophobic residues, such as Y. Conversely, other B7 supertype alleles, such as B\*5401, seem to prefer small hydrophobic residues, such as A, at the C-terminus. While we have noted these subtle differences in preference [20], in practice we have not found that they significantly impact cross-reactivity between the alleles. This perhaps suggests that the C-terminal anchor in some contexts is less important, and that shared secondary preferences can have a stronger influence on degenerate binding capacity than in other cases. At the same time, it may be necessary to consider additional key residues in the analysis of the F pocket. This is exemplified in the cases of A\*2603 and A\*0301 which have the same key F pocket residues, but which are associated with much different specificity.

The vast majority of HLA-A and -B alleles fall into one of the 9 superotypes we have described. There are likely reasons for this [110], which include evolutionary relationships, but also constraints and limitations inherent in the epitope processing infrastructure. For example, no allele has been identified to date that binds peptides with D, E, Q or P at the C-terminus, which is in congruence with the preferences of both proteasomal cleavage and TAP transport [111], and an observation that has been applied in the rational design of an in vitro test reagent tool (Pept-Gen) offered as a tool by the Los Alamos HIV Sequence Database [112].

Supertype classification should not be taken to necessarily imply an evolutionary relationship. In some cases this is largely true, as for example in the case of the A2-supertype, where most alleles are associated with the A2 serological antigen. In other cases the relationship is more complicated, such as the gene conversion relationship between the A2, A3 and A68 antigens. This latter example is somewhat of the exception that proves the rule. Supertype associations are based on shared binding specificity, which may result from both common ancestry and convergent evolution [110]. Thus, while alleles within a supertype may have a close evolutionary relationship, that is not a given. Also, alleles (superotypes) sharing specificity at one anchor position may be associated with very disparate specificities at the other.

Other groups have also utilized various methodologies to define superotypes. In general, our classification is in agreement with those derived by other approaches, as compiled by Hertz [32], Lund [23] and Tong [31]. This is not surprising given the good agreement observed between our initial dataset and other classifications, and that the methodology utilized here is not different from the one utilized to derive the original assignments. If there are variations, they usually represent the splitting of a supertype,

or reassignment of individual alleles. As in any classification problem of this kind, there is no absolute truth in supertype assignments. The practical application of supertype classification schemes to identify degenerately binding peptides will ultimately show what classification scheme has the most practical value.

## Conclusion

The present study represents an update to the HLA class I supertype classification originally described almost a decade ago. Using MHC peptide binding motif data and MHC sequence information that has since become available, supertype associations have now been provided for over 750 HLA-A and -B alleles. In addition, the approach utilized has been made more transparent, allowing others to utilize the classification approach going forward.

## Methods

### MHC sequences

The sequences of HLA A and B class I alleles were obtained from the IMGT/HLA Database [91,113], release 2.9. Alleles with incomplete sequences were removed from further analysis. The residues forming the B and F peptide binding pockets were aligned as described in the Results section.

### Peptide binding motif reference panel

The main anchor peptide binding motifs recognized by HLA-A and -B molecules were compiled from our own data, or as reported at the SYFPEITHI database [87]. The HLA supertype associated with each motif was assigned as defined previously [11,12], and/or on the basis of the broad chemical specificity of each supertype indicated in Tables 1 and 2.

### Pocket analysis

The residues forming the B and F pockets of each allele in the motif reference panel were compiled as a lookup table in Microsoft Excel. Pockets were defined more stringently by considering all residues forming the pocket, or less stringently by considering only a subset of residues, denominated as key residues, hypothesized to be most directly involved in peptide binding. To assign a B and F pocket specificity for each of the remaining alleles, the reference panel was scanned to identify exact pocket sequence matches. If an exact match could be identified, the allele was assigned the corresponding B or F pocket specificity. Supertype assignments were then made by matching the B and F pocket specificity pattern with the supertype descriptions indicated in Table 2. If an exact match for either the full pocket sequence or key residue sequence could not be made at both the B and F pockets, the allele was considered unassigned.

## Abbreviations

EBV (Epstein-Barr virus); HBV (hepatitis B virus); HCV (hepatitis C virus); HIV (human immunodeficiency virus); HLA (human leukocyte antigen); HPV (human papilloma virus); IEDB (Immune Epitope Database); LCMV (lymphocytic choriomeningitis virus); MHC (major histocompatibility complex); SARS (severe acute respiratory syndrome).

## Authors' contributions

JS performed the sequence analyses, determined the supertype assignments and drafted the manuscript. BP participated in the conceptualization and design of the study, and assisted in the preparation of the manuscript. NF and CB assisted in the study design and data interpretation. AS participated in conceptualization of the study and its design, provided interpretation of the data, and helped to draft the manuscript. All authors read and approved the final manuscript.

## Additional material

### Additional file 1

*HLA supertype classification of HLA A and B class I alleles. This table provides a complete listing of the HLA A and B alleles examined in the present study. The table is sorted in alphanumeric order to facilitate searching for a specific allele. For each allele, the supertype assignment is indicated, and its corresponding B and F pocket sequences are shown.*

Click here for file

[<http://www.biomedcentral.com/content/supplementary/1471-2172-9-1-S1.xls>]

## Acknowledgements

Efforts for this study were supported by funds from NIH-NIAID contracts N01-AI-40023, N01-AI-40024 and HHSN266200400006C to AS.

## References

1. Guo HC, Jardetzky TS, Garrett TP, Lane WS, Strominger JL, Wiley DC: **Different length peptides bind to HLA-Aw68 similarly at their ends but bulge out in the middle.** *Nature* 1992, **360**:364-6.
2. Silver ML, Guo HC, Strominger JL, Wiley DC: **Atomic structure of a human MHC molecule presenting an influenza virus peptide.** *Nature* 1992, **360**:367-9.
3. Gorga JC, Madden DR, Prendergast JK, Wiley DC, Strominger JL: **Crystallization and preliminary X-ray diffraction studies of the human major histocompatibility antigen HLA-B27.** *Proteins* 1992, **12**:87-90.
4. Madden DR: **The three-dimensional structure of peptide-MHC complexes.** *Annu Rev Immunol* 1995, **13**:587-622.
5. Madden DR, Garboczi DN, Wiley DC: **The antigenic identity of peptide-MHC complexes: a comparison of the conformations of five viral peptides presented by HLA-A2.** *Cell* 1993, **75**:693-708.
6. Madden DR, Gorga JC, Strominger JL, Wiley DC: **The three-dimensional structure of HLA-B27 at 2.1 Å resolution suggests a general mechanism for tight peptide binding to MHC.** *Cell* 1992, **70**:1035-48.
7. Bjorkman PJ, Saper MA, Samraoui B, Bennett WS, Strominger JL, Wiley DC: **The foreign antigen binding site and T cell recognition regions of class I histocompatibility antigens.** *Nature* 1987, **329**:512-8.

8. Saper MA, Bjorkman PJ, Wiley DC: **Refined structure of the human histocompatibility antigen HLA-A2 at 2.6 Å resolution.** *J Mol Biol* 1991, **219**:277-319.
9. Falk K, Rotzschke O, Stevanovic S, Jung G, Rammensee HG: **Allele-specific motifs revealed by sequencing of self-peptides eluted from MHC molecules.** *Nature* 1991, **351**:290-6.
10. Sidney J, Grey HM, Kubo RT, Sette A: **Practical, biochemical and evolutionary implications of the discovery of HLA class I supermotifs.** *Immunol Today* 1996, **17**:261-6.
11. Sette A, Sidney J: **HLA supertypes and supermotifs: a functional perspective on HLA polymorphism.** *Curr Opin Immunol* 1998, **10**:478-82.
12. Sette A, Sidney J: **Nine major HLA class I supertypes account for the vast preponderance of HLA-A and -B polymorphism.** *Immunogenetics* 1999, **50**:201-12.
13. del Guercio MF, Sidney J, Hermanson G, Perez C, Grey HM, Kubo RT, Sette A: **Binding of a peptide antigen to multiple HLA alleles allows definition of an A2-like supertype.** *J Immunol* 1995, **154**:685-93.
14. Sidney J, del Guercio MF, Southwood S, Hermanson G, Maewal A, Appella E, Sette A: **The HLA-A\*0207 peptide binding repertoire is limited to a subset of the A\*0201 repertoire.** *Hum Immunol* 1997, **58**:12-20.
15. Sidney J, Southwood S, Mann DL, Fernandez-Vina MA, Newman MJ, Sette A: **Majority of peptides binding HLA-A\*0201 with high affinity crossreact with other A2-supertype molecules.** *Hum Immunol* 2001, **62**:1200-16.
16. Chang KM, Gruener NH, Southwood S, Sidney J, Pape GR, Chisari FV, Sette A: **Identification of HLA-A3 and -B7-restricted CTL response to hepatitis C virus in patients with acute and chronic hepatitis C.** *J Immunol* 1999, **162**:1156-64.
17. Sidney J, Grey HM, Southwood S, Celis E, Wentworth PA, delGuercio MF, Kubo RT, Chesnut RW, Sette A: **Definition of an HLA-A3-like supermotif demonstrates the overlapping peptide-binding repertoires of common HLA molecules.** *Hum Immunol* 1996, **45**:79-93.
18. Threlkeld SC, Wentworth PA, Kalams SA, Wilkes BM, Ruhl DJ, Keogh E, Sidney J, Southwood S, Walker BD, Sette A: **Degenerate and promiscuous recognition by CTL of peptides presented by the MHC class I A3-like superfamily: implications for vaccine development.** *J Immunol* 1997, **159**:1648-57.
19. Sidney J, del Guercio MF, Southwood S, Engelhard VH, Appella E, Rammensee HG, Falk K, Rotzschke O, Takiguchi M, Kubo RT, et al.: **Several HLA alleles share overlapping peptide specificities.** *J Immunol* 1995, **154**:247-59.
20. Sidney J, Southwood S, del Guercio MF, Grey HM, Chesnut RW, Kubo RT, Sette A: **Specificity and degeneracy in peptide binding to HLA-B7-like class I molecules.** *J Immunol* 1996, **157**:3480-90.
21. Sidney J, Southwood S, Pasquetto V, Sette A: **Simultaneous prediction of binding capacity for multiple molecules of the HLA B44-supertype.** *J Immunol* 2003, **171**:5964-5974.
22. Sidney J, Southwood S, Sette A: **Classification of A1- and A24-supertype molecules by analysis of their MHC-peptide binding repertoires.** *Immunogenetics* 2005, **57**:393-408.
23. Lund O, Nielsen M, Kesmir C, Petersen AG, Lundegaard C, Worning P, Sylvester-Hvid C, Lamberth K, Roder G, Justesen S, et al.: **Definition of supertypes for HLA molecules using clustering of specificity matrices.** *Immunogenetics* 2004, **55**:797-810.
24. Zhang C, Anderson A, DeLisi C: **Structural principles that govern the peptide-binding motifs of class I MHC molecules.** *J Mol Biol* 1998, **281**:929-47.
25. Cano P, Fan B, Stass S: **A geometric study of the amino acid sequence of class I HLA molecules.** *Immunogenetics* 1998, **48**:324-34.
26. Doytchinova IA, Guan P, Flower DR: **Identifying human MHC supertypes using bioinformatic methods.** *J Immunol* 2004, **172**:4314-23.
27. Reche PA, Reinherz EL: **Definition of MHC supertypes through clustering of MHC peptide binding repertoires.** *LNCS, ICARIS* 2004, **3239**:189-196.
28. Chelvanayagam G: **A roadmap for HLA-A, HLA-B, and HLA-C peptide binding specificities.** *Immunogenetics* 1996, **45**:15-26.
29. Kanguane P, Sakharkar MK, Rajaseger G, Bolisetty S, Sivasekari B, Zhao B, Ravichandran M, Shapshak P, Subbiah S: **A framework to sub-type HLA supertypes.** *Front Biosci* 2005, **10**:879-86.
30. Zhao B, Png AE, Ren EC, Kolatkar PR, Mathura VS, Sakharkar MK, Kanguane P: **Compression of functional space in HLA-A sequence diversity.** *Hum Immunol* 2003, **64**:718-28.
31. Tong JC, Tan TW, Ranganathan S: **In silico grouping of peptide/HLA class I complexes using structural interaction characteristics.** *Bioinformatics* 2007, **23**:177-83.
32. Hertz T, Yanover C: **Identifying HLA supertypes by learning distance functions.** *Bioinformatics* 2007, **23**:e148-55.
33. Ovsyannikova IG, Jacobson RM, Vierkant RA, Pankratz VS, Poland GA: **HLA supertypes and immune responses to measles-mumps-rubella viral vaccine: findings and implications for vaccine design.** *Vaccine* 2007, **25**:3090-100.
34. Sylvester-Hvid C, Nielsen M, Lamberth K, Roder G, Justesen S, Lundegaard C, Worning P, Thomadsen H, Lund O, Brunak S, et al.: **SARS CTL vaccine candidates; HLA supertype-, genome-wide scanning and biochemical validation.** *Tissue Antigens* 2004, **63**:395-400.
35. Burrows SR, Elkington RA, Miles JJ, Green KJ, Walker S, Haryana SM, Moss DJ, Dunkley H, Burrows JM, Khanna R: **Promiscuous CTL recognition of viral epitopes on multiple human leukocyte antigens: biological validation of the proposed HLA A24 supertype.** *J Immunol* 2003, **171**:1407-12.
36. Khanna R, Burrows SR, Nicholls J, Poulsen LM: **Identification of cytotoxic T cell epitopes within Epstein-Barr virus (EBV) oncogene latent membrane protein 1 (LMP1): evidence for HLA A2 supertype-restricted immune recognition of EBV-infected cells by LMP1-specific cytotoxic T lymphocytes.** *Eur J Immunol* 1998, **28**:451-8.
37. Trachtenberg E, Korber B, Sollars C, Kepler TB, Hraber PT, Hayes E, Funkhouser R, Fugate M, Theiler J, Hsu YS, et al.: **Advantage of rare HLA supertype in HIV disease progression.** *Nat Med* 2003, **9**:928-35.
38. Wilson CC, McKinney D, Anders M, MaWhinney S, Forster J, Crimi C, Southwood S, Sette A, Chesnut R, Newman MJ, et al.: **Development of a DNA vaccine designed to induce cytotoxic T lymphocyte responses to Multiple conserved epitopes in HIV-1.** *J Immunol* 2003, **171**:5611-23.
39. Altfeld MA, Livingston B, Reshamwala N, Nguyen PT, Addo MM, Shea A, Newman M, Fikes J, Sidney J, Wentworth P, et al.: **Identification of novel HLA-A2-restricted human immunodeficiency virus type 1-specific cytotoxic T-lymphocyte epitopes predicted by the HLA-A2 supertype peptide-binding motif.** *J Virol* 2001, **75**:1301-11.
40. Lichtenfeld KL, Williams M, Mui SK, Shah SS, Mothe BR, Sette A, Kim A, Johnston MN, Burgett N, Frahm N, et al.: **T cell receptor cross-recognition of an HIV-1 CD8+ T cell epitope presented by closely related alleles from the HLA-A3 superfamily.** *Int Immunol* 2006, **18**:1179-88.
41. Honeyborne I, Rathod A, Buchli R, Ramduth D, Moodley E, Rathnavalu P, Chetty S, Day C, Brander C, Hildebrandt W, et al.: **Motif inference reveals optimal CTL epitopes presented by HLA class I alleles highly prevalent in southern Africa.** *J Immunol* 2006, **176**:4699-705.
42. Bihl F, Narayan M, Chisholm JV 3rd, Henry LM, Suscovich TJ, Brown EE, Welzel TM, Kaufmann DE, Zaman TM, Dollard S, et al.: **Lytic and latent antigens of the human gammaherpesviruses Kaposi's sarcoma-associated herpesvirus and Epstein-Barr virus induce T-cell responses with similar functional properties and memory phenotypes.** *J Virol* 2007, **81**:4904-8.
43. Brander C, O'Connor P, Suscovich T, Jones NG, Lee Y, Kedes D, Ganem D, Martin J, Osmond D, Southwood S, et al.: **Definition of an optimal cytotoxic T lymphocyte epitope in the latently expressed Kaposi's sarcoma-associated herpesvirus kaposin protein.** *J Infect Dis* 2001, **184**:119-26.
44. Wentworth PA, Sette A, Celis E, Sidney J, Southwood S, Crimi C, Stitely S, Keogh E, Wong NC, Livingston B, et al.: **Identification of A2-restricted hepatitis C virus-specific cytotoxic T lymphocyte epitopes from conserved regions of the viral genome.** *Int Immunol* 1996, **8**:651-9.
45. Berton R, Sidney J, Fowler P, Chesnut RW, Chisari FV, Sette A: **Human histocompatibility leukocyte antigen-binding supermotifs predict broadly cross-reactive cytotoxic T lymphocyte responses in patients with acute hepatitis.** *J Clin Invest* 1997, **100**:503-13.
46. Livingston BD, Crimi C, Fikes J, Chesnut RW, Sidney J, Sette A: **Immunization with the HBV core 18-27 epitope elicits CTL**

- responses in humans expressing different HLA-A2 supertype molecules. *Hum Immunol* 1999, **60**:1013-7.
47. Rensing ME, de Jong JH, Brandt RM, Drijfhout JW, Benckhuijsen WE, Schreuder GM, Offringa R, Kast WM, Melief CJ: **Differential binding of viral peptides to HLA-A2 alleles. Implications for human papillomavirus type 16 E7 peptide-based vaccination against cervical carcinoma.** *Eur J Immunol* 1999, **29**:1292-303.
  48. Zhang HG, Pang XW, Shang XY, Xing Q, Chen WF: **Functional supertype of HLA-A2 in the presentation of Flu matrix p58-66 to induce CD8+ T-cell response in a Northern Chinese population.** *Tissue Antigens* 2003, **62**:285-95.
  49. Lyke KE, Burges RB, Cissoko Y, Sangare L, Kone A, Dao M, Diarra I, Fernandez-Vina MA, Plowe CV, Doumbo OK, et al.: **HLA-A2 supertype-restricted cell-mediated immunity by peripheral blood mononuclear cells derived from Malian children with severe or uncomplicated Plasmodium falciparum malaria and healthy controls.** *Infect Immun* 2005, **73**:5799-808.
  50. Doolan DL, Hoffman SL, Southwood S, Wentworth PA, Sidney J, Chesnut RW, Keogh E, Appella E, Nutman TB, Lal AA, et al.: **Degenerate cytotoxic T cell epitopes from P. falciparum restricted by multiple HLA-A and HLA-B supertype alleles.** *Immunity* 1997, **7**:97-112.
  51. Doolan DL, Southwood S, Freilich DA, Sidney J, Graber NL, Shatney L, Bebris L, Florens L, Dobano C, Witney AA, et al.: **Identification of Plasmodium falciparum antigens by antigenic analysis of genomic and proteomic data.** *Proc Natl Acad Sci USA* 2003, **100**:9952-7.
  52. Tang Y, Lin Y, Mao Y, Dong M, Wang H: **Cross-binding between Plasmodium falciparum CTL epitopes and HLA class I molecules.** *Immunol Invest* 2003, **32**:31-41.
  53. Botten J, Whittom JL, Barrowman P, Sidney J, Whitmire JK, Alexander J, Ting JP, Bui HH, Sette A, Buchmeier MJ: **HLA-A2-restricted protection against lethal lymphocytic choriomeningitis.** *J Virol* 2007, **81**:2307-17.
  54. Botten J, Alexander J, Pasquetto V, Sidney J, Barrowman P, Ting J, Peters B, Southwood S, Stewart B, Rodriguez-Carreno MP, et al.: **Identification of protective Lassa virus epitopes that are restricted by HLA-A2.** *J Virol* 2006, **80**:8351-61.
  55. McMurry JA, Gregory SH, Moise L, Rivera D, Buus S, De Groot AS: **Diversity of Francisella tularensis Schu4 antigens recognized by T lymphocytes after natural infections in humans: identification of candidate epitopes for inclusion in a rationally designed tularemia vaccine.** *Vaccine* 2007, **25**:3179-91.
  56. Ostrout ND, McHugh MM, Tisch DJ, Moormann AM, Brusic V, Kazura JW: **Long-term T cell memory to human leucocyte antigen-A2 supertype epitopes in humans vaccinated against smallpox.** *Clin Exp Immunol* 2007.
  57. Oseroff C, Kos F, Bui HH, Peters B, Pasquetto V, Glenn J, Palmore T, Sidney J, Tschärke DC, Bennink JR, et al.: **HLA class I-restricted responses to vaccinia recognize a broad array of proteins mainly involved in virulence and viral gene regulation.** *Proc Natl Acad Sci USA* 2005, **102**:13980-5.
  58. Pasquetto V, Bui HH, Giannino R, Mirza F, Sidney J, Oseroff C, Tschärke DC, Irvine K, Bennink JR, Peters B, et al.: **HLA-A\* HLA-A\*1101, and HLA-B\*0702 Transgenic Mice Recognize Numerous Poxvirus Determinants from a Wide Variety of Viral Gene Products.** *J Immunol* 2001, **175**:5504-15.
  59. Fikes JD, Sette A: **Design of multi-epitope, analogue-based cancer vaccines.** *Expert Opin Biol Ther* 2003, **3**:985-93.
  60. Kawashima I, Hudson SJ, Tsai V, Southwood S, Takesako K, Appella E, Sette A, Celis E: **The multi-epitope approach for immunotherapy for cancer: identification of several CTL epitopes from various tumor-associated antigens expressed on solid epithelial tumors.** *Hum Immunol* 1998, **59**:1-14.
  61. Kawashima I, Tsai V, Southwood S, Takesako K, Celis E, Sette A: **Identification of gp100-derived, melanoma-specific cytotoxic T-lymphocyte epitopes restricted by HLA-A3 supertype molecules by primary in vitro immunization with peptide-pulsed dendritic cells.** *Int J Cancer* 1998, **78**:518-24.
  62. Keogh E, Fikes J, Southwood S, Celis E, Chesnut R, Sette A: **Identification of new epitopes from four different tumor-associated antigens: recognition of naturally processed epitopes correlates with HLA-A\*0201-binding affinity.** *J Immunol* 2001, **167**:787-96.
  63. Wang RF, Johnston SL, Southwood S, Sette A, Rosenberg SA: **Recognition of an antigenic peptide derived from tyrosinase-related protein-2 by CTL in the context of HLA-A31 and -A33.** *J Immunol* 1998, **160**:890-7.
  64. Kawashima I, Tsai V, Southwood S, Takesako K, Sette A, Celis E: **Identification of HLA-A3-restricted cytotoxic T lymphocyte epitopes from carcinoembryonic antigen and HER-2/neu by primary in vitro immunization with peptide-pulsed dendritic cells.** *Cancer Res* 1999, **59**:431-5.
  65. Matsueda S, Takedatsu H, Sasada T, Azuma K, Ishihara Y, Komohara Y, Noguchi M, Shichijo S, Itoh K, Harada M: **New peptide vaccine candidates for epithelial cancer patients with HLA-A3 supertype alleles.** *J Immunother (1997)* 2007, **30**:274-81.
  66. Minami T, Matsueda S, Takedatsu H, Tanaka M, Noguchi M, Uemura H, Itoh K, Harada M: **Identification of SART3-derived peptides having the potential to induce cancer-reactive cytotoxic T lymphocytes from prostate cancer patients with HLA-A3 supertype alleles.** *Cancer Immunol Immunother* 2007, **56**:689-98.
  67. Takedatsu H, Shichijo S, Katagiri K, Sawamizu H, Sata M, Itoh K: **Identification of peptide vaccine candidates sharing among HLA-A3+, -A11+, -A31+, and -A33+ cancer patients.** *Clin Cancer Res* 2004, **10**:1112-20.
  68. Matsueda S, Takedatsu H, Yao A, Tanaka M, Noguchi M, Itoh K, Harada M: **Identification of peptide vaccine candidates for prostate cancer patients with HLA-A3 supertype alleles.** *Clin Cancer Res* 2005, **11**:6933-43.
  69. Brusic V, Petrovsky N, Zhang G, Bajic VB: **Prediction of promiscuous peptides that bind HLA class I molecules.** *Immunol Cell Biol* 2002, **80**:280-5.
  70. Khan AM, Miotto O, Heiny AT, Salmon J, Srinivasan KN, Nascimento EJ, Marques ET Jr, Brusic V, Tan TW, August JT: **A systematic bioinformatics approach for selection of epitope-based vaccine targets.** *Cell Immunol* 2006, **244**:141-7.
  71. Reche PA, Reinherz EL: **PEPVAC: a web server for multi-epitope vaccine development based on the prediction of supertypic MHC ligands.** *Nucleic Acids Res* 2005, **33**:W138-42.
  72. Zhu S, Udaka K, Sidney J, Sette A, Aoki-Kinoshita KF, Mamitsuka H: **Improving MHC binding peptide prediction by incorporating binding data of auxiliary MHC molecules.** *Bioinformatics* 2006, **22**:1648-55.
  73. Zhang GL, Khan AM, Srinivasan KN, August JT, Brusic V: **MULTIPRED: a computational system for prediction of promiscuous HLA binding peptides.** *Nucleic Acids Res* 2005, **33**:W172-9.
  74. Hogan KT, Sutton JN, Chu KU, Busby JA, Shabanowitz J, Hunt DF, Slingluff CL Jr: **Use of selected reaction monitoring mass spectrometry for the detection of specific MHC class I peptide antigens on A3 supertype family members.** *Cancer Immunol Immunother* 2005, **54**:359-71.
  75. Doytchinova I, Flower DR: **The HLA-A2-supermotif: a QSAR definition.** *Org Biomol Chem* 2003, **1**:2648-54.
  76. Guan P, Doytchinova IA, Flower DR: **A comparative molecular similarity indices (CoMSIA) study of peptide binding to the HLA-A3 superfamily.** *Bioorg Med Chem* 2003, **11**:2307-11.
  77. Guan P, Doytchinova IA, Flower DR: **HLA-A3 supermotif defined by quantitative structure-activity relationship analysis.** *Protein Eng* 2003, **16**:11-8.
  78. MacDonald KS, Fowke KR, Kimani J, Dunand VA, Nagelkerke NJ, Ball TB, Oyugi J, Njagi E, Gaur LK, Brunham RC, et al.: **Influence of HLA supertypes on susceptibility and resistance to human immunodeficiency virus type 1 infection.** *J Infect Dis* 2000, **181**:1581-9.
  79. MacDonald KS, Embree JE, Nagelkerke NJ, Castillo J, Ramhadin S, Njenga S, Oyugi J, Ndinya-Achola J, Barber BH, Bwayo JJ, et al.: **The HLA A2/6802 supertype is associated with reduced risk of perinatal human immunodeficiency virus type 1 transmission.** *J Infect Dis* 2001, **183**:503-6.
  80. MacDonald KS, Matukas L, Embree JE, Fowke K, Kimani J, Nagelkerke NJ, Oyugi J, Kiama P, Kaul R, Luscher MA, et al.: **Human leucocyte antigen supertypes and immune susceptibility to HIV-1, implications for vaccine design.** *Immunol Lett* 2001, **79**:151-7.
  81. Stephens HA: **HIV-1 diversity versus HLA class I polymorphism.** *Trends Immunol* 2005, **26**:41-7.
  82. Balamurugan A, Sharma SK, Mehra NK: **Human leukocyte antigen class I supertypes influence susceptibility and severity of tuberculosis.** *J Infect Dis* 2004, **189**:805-11.
  83. Lopez-Vazquez A, Mina-Blanco A, Martinez-Borra J, Njobvu PD, Suarez-Alvarez B, Blanco-Gelaz MA, Gonzalez S, Rodrigo L, Lopez-Larrea C: **Interaction between KIR3DL1 and HLA-B\*57 supertype**



- alleles influences the progression of HIV-1 infection in a Zambian population. *Hum Immunol* 2005, **66**:285-9.
84. Lopez-Larrea C, Mijiyawa M, Gonzalez S, Fernandez-Morera JL, Blanco-Gelaz MA, Martinez-Borra J, Lopez-Vazquez A: **Association of ankylosing spondylitis with HLA-B\*1403 in a West African population.** *Arthritis Rheum* 2002, **46**:2968-71.
  85. Novitsky V, Gilbert P, Peter T, McLane MF, Gaolekwe S, Rybak N, Thior I, Ndung'u T, Marlink R, Lee TH, et al.: **Association between virus-specific T-cell responses and plasma viral load in human immunodeficiency virus type 1 subtype C infection.** *J Virol* 2003, **77**:882-90.
  86. Scherer A, Frater J, Oxenius A, Agudelo J, Price DA, Gunthard HF, Barnardo M, Perrin L, Hirschel B, Phillips RE, et al.: **Quantifiable cytotoxic T lymphocyte responses and HLA-related risk of progression to AIDS.** *Proc Natl Acad Sci USA* 2004, **101**:12266-70.
  87. Rammensee H, Bachmann J, Emmerich NP, Bachor OA, Stevanovic S: **SYFPEITHI: database for MHC ligands and peptide motifs.** *Immunogenetics* 1999, **50**:213-9.
  88. Sathiamurthy M, Hickman HD, Cavett JW, Zahoor A, Prilliman K, Metcalf S, Fernandez Vina M, Hildebrand WH: **Population of the HLA ligand database.** *Tissue Antigens* 2003, **61**:12-9.
  89. Schonbach C, Koh JL, Flower DR, Wong L, Brusci V: **FIMM, a database of functional molecular immunology: update 2002.** *Nucleic Acids Res* 2002, **30**:226-9.
  90. Bhasin M, Singh H, Raghava GP: **MHCBN: a comprehensive database of MHC binding and non-binding peptides.** *Bioinformatics* 2003, **19**:665-6.
  91. Robinson J, Waller MJ, Parham P, de Groot N, Bontrop R, Kennedy LJ, Stoeckl P, Marsh SG: **IMGT/HLA and IMGT/MHC: sequence databases for the study of the major histocompatibility complex.** *Nucleic Acids Res* 2003, **31**:311-4.
  92. Falk K, Rotzschke O, Takiguchi M, Gnau V, Stevanovic S, Jung G, Rammensee HG: **Peptide motifs of HLA-B58, B60, B61, and B62 molecules.** *Immunogenetics* 1995, **41**:165-8.
  93. Prilliman KR, Jackson KW, Lindsey M, Wang J, Crawford D, Hildebrand WH: **HLA-B15 peptide ligands are preferentially anchored at their C termini.** *J Immunol* 1999, **162**:7277-84.
  94. **The Immune epitope database and analysis resource** [<http://www.immuneepitope.org>]
  95. Peters B, Sette A: **Integrating epitope data into the emerging web of biomedical knowledge resources.** *Nat Rev Immunol* 2007, **7**:485-90.
  96. Peters B, Sidney J, Bourne P, Bui HH, Buus S, Doh G, Fleri W, Kronenberg M, Kubo R, Lund O, et al.: **The immune epitope database and analysis resource: from vision to blueprint.** *PLoS Biol* 2005, **3**:e91.
  97. Frahm N, Yusim K, Suscovich TJ, Adams S, Sidney J, Hrabec P, Hewitt HS, Linde CH, Kavanagh DG, Woodberry T, et al.: **Extensive HLA class I allele promiscuity among viral CTL epitopes.** *Eur J Immunol* 2007, **37**:2419-33.
  98. Assarsson E, Sidney J, Oseroff C, Pasquetto V, Bui HH, Frahm N, Brander C, Peters B, Grey H, Sette A: **A quantitative analysis of the variables affecting the repertoire of T cell specificities recognized after vaccinia virus infection.** *J Immunol* 2007, **178**:7890-901.
  99. Bihl F, Frahm N, Di Giammarino L, Sidney J, John M, Yusim K, Woodberry T, Sango K, Hewitt HS, Henry L, et al.: **Impact of HLA-B alleles, epitope binding affinity, functional avidity, and viral coinfection on the immunodominance of virus-specific CTL responses.** *J Immunol* 2006, **176**:4094-101.
  100. Altfeld M, Allen TM, Kalife ET, Frahm N, Addo MM, Mothe BR, Rathod A, Reyrol LL, Harlow J, Yu XG, et al.: **The majority of currently circulating human immunodeficiency virus type 1 clade B viruses fail to prime cytotoxic T-lymphocyte responses against an otherwise immunodominant HLA-A2-restricted epitope: implications for vaccine design.** *J Virol* 2005, **79**:5000-5.
  101. Leslie A, Price DA, Mkhize P, Bishop K, Rathod A, Day C, Crawford H, Honeyborne I, Asher TE, Luzzi G, et al.: **Differential selection pressure exerted on HIV by CTL targeting identical epitopes but restricted by distinct HLA alleles from the same HLA supertype.** *J Immunol* 2006, **177**:4699-708.
  102. Macdonald WA, Purcell AW, Mifsud NA, Ely LK, Williams DS, Chang L, Gorman JJ, Clements CS, Kjer-Nielsen L, Koelle DM, et al.: **A naturally selected dimorphism within the HLA-B44 supertype alters class I structure, peptide repertoire, and T cell recognition.** *J Exp Med* 2003, **198**:679-91.
  103. Apostolopoulos V, Yu M, Corper AL, Li W, McKenzie IF, Teyton L, Wilson IA, Plebanski M: **Crystal structure of a non-canonical high affinity peptide complexed with MHC class I: a novel use of alternative anchors.** *J Mol Biol* 2002, **318**:1307-16.
  104. Apostolopoulos V, Yu M, Corper AL, Teyton L, Pietersz GA, McKenzie IF, Wilson IA, Plebanski M: **Crystal structure of a non-canonical low-affinity peptide complexed with MHC class I: a new approach for vaccine design.** *J Mol Biol* 2002, **318**:293-305.
  105. Fremont DH, Stura EA, Matsumura M, Peterson PA, Wilson IA: **Crystal structure of an H-2Kb-ovalbumin peptide complex reveals the interplay of primary and secondary anchor positions in the major histocompatibility complex binding groove.** *Proc Natl Acad Sci USA* 1995, **92**:2479-83.
  106. Hengel H, Burke K, Kyburz D, Zinkernagel RM, Koszinowski UH: **Peptides control the gain and loss of allele specificity by mutated MHC class I molecules.** *J Immunol* 1995, **154**:4557-64.
  107. Li H, Natarajan K, Malchiodi EL, Margulies DH, Mariuzza RA: **Three-dimensional structure of H-2Dd complexed with an immunodominant peptide from human immunodeficiency virus envelope glycoprotein 120.** *J Mol Biol* 1998, **283**:179-91.
  108. Mata M, Travers PJ, Liu Q, Frankel FR, Paterson Y: **The MHC class I-restricted immune response to HIV-gag in BALB/c mice selects a single epitope that does not have a predictable MHC-binding motif and binds to Kd through interactions between a glutamine at P3 and pocket D.** *J Immunol* 1998, **161**:2985-93.
  109. Mitaksov V, Fremont DH: **Structural definition of the H-2Kd peptide-binding motif.** *J Biol Chem* 2006, **281**:10618-25.
  110. Sette A, Sidney J, Livingston B, Dzuris J, Crimi C, Walker CM, Southwood S, Collins EJ, Hughes A: **Class I molecules with similar peptide binding specificities are the result of both common ancestry and convergent evolution.** *Immunogenetics* 2003, **54**:830-841.
  111. Tenzer S, Peters B, Bulik S, Schoor O, Lemmel C, Schatz MM, Kloetzel PM, Rammensee HG, Schild H, Holzhtutter HG: **Modeling the MHC class I pathway by combining predictions of proteasomal cleavage, TAP transport and MHC class I binding.** *Cell Mol Life Sci* 2005, **62**:1025-37.
  112. **Los Alamos HIV Sequence Database** [<http://www.hiv.lanl.gov>]
  113. **IMGT/HLA Database** [<http://www.ebi.ac.uk/imgt/hla/>]

Publish with **BioMed Central** and every scientist can read your work free of charge

"BioMed Central will be the most significant development for disseminating the results of biomedical research in our lifetime."

Sir Paul Nurse, Cancer Research UK

Your research papers will be:

- available free of charge to the entire biomedical community
- peer reviewed and published immediately upon acceptance
- cited in PubMed and archived on PubMed Central
- yours — you keep the copyright

Submit your manuscript here:  
[http://www.biomedcentral.com/info/publishing\\_adv.asp](http://www.biomedcentral.com/info/publishing_adv.asp)

